Please assess the completion status of the following clinical trial:

Trial Title: Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Brain MRI-confirmed 1-10 solid tumor brain metastases~2. Biopsy-confirmed primary malignancy~3. ds-GPA estimated median survival of at least 6 months, for histologies not included in the ds-GPA, publications or noted online at brainmetgpa.com, the PI will use either published or validated data or their best clinical judgment to determine the patient's expected survival~4. Stereotactic radiosurgery candidate per treating Radiation Oncologist~5. ≥ 18 years old at the time of informed consent~6. Ability to provide written informed consent and HIPAA (Health Insurance Portability and Accountability Act) authorization.~7. ALC \> 800/ul (Ku et al., 2010)~8. Patients currently on cytotoxic chemotherapy are eligible~9. Patients receiving ICI up to 30 days prior to delivery of SRS are eligible~10. Patients having undergone operative resection for metastatic brain disease within 30 days of immune checkpoint inhibitor (ICI) administration are eligible.~Exclusion Criteria:~1. Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and/or interfere with follow-up~2. Patients unable to receive MRI Brain~3. Patients with more than 10 brain metastases on MRI Brain imaging~4. Any lesion \> 4 centimeter maximum diameter~5. Total volume of metastatic disease more than 30 cubic centimeters~6. Previous whole brain radiation therapy~7. For Cohort 1: Previous stereotactic radiosurgery where the 50% isodose line overlaps with current treatment field~8. For Cohort 2: Patients whose treatment will have a dose overlap within the target from prior treatments of 20% or greater~9. Already receiving chronic dexamethasone (chronic = \> 2 weeks) prior to SRS~10. Not a radiosurgical candidate per Radiation Oncology discretion~11. Existing autoimmune disease~12. Patients who have an unknown primary cancer~13. Histology not amenable for SRS (i.e. lymphoma). (Small Cell Lung Cancer IS amenable.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reduced Dose Stereotactic Radiosurgery (Type: EXPERIMENTAL): Subjects will receive one stereotactic radiosurgery (SRS) treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 3, 6, 9, and 12 months post SRS treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).